1. Israel Stocks

  2. •

    Process industries

  3. •

    Agricultural commodities/Milling
Tikun Olam-Cannbit Pharmaceuticals Ltd.

Tikun Olam-Cannbit Pharmaceuticals Ltd.

TTASE:TKUN-M
120,000.00
ILA
+27,800.00
(+30.15%)
Tikun Olam-Cannbit Pharmaceuticals Ltd.
TASE:TKUN-M
(Tel Aviv Stock Exchange)

Recent

price

120,000.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ILS
- -
- -
- -
- -
- -
- -
- -
- -
- -
29,737.34
44,069.8
48,526.4
35,092.23
20,872.75
5,356.35
- -
Revenue per Share
19,207.23
-17,806.71
-11,711.03
-3,749.77
-2,496.91
-796.12
-1.46
-279.89
-27,869.78
-45,229.37
-38,858.3
-47,481
-70,525.64
-23,947.64
-9,329.19
- -
Basic EPS, GAAP
-2,680.78
-2,592.23
-2,121.72
-1,798.17
-2,148.28
-469.55
-0.93
-46.07
-41,735.56
-69,604.98
-39,852.05
-29,653.11
-3,268.18
-2,257.95
1,182.85
- -
Free Cash Flow per Basic Share
23,809.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
22,520.74
9,744.92
7,030.01
4,541.92
3,745.81
17.55
1.11
166,950.17
168,271.98
152,958.07
101,175.49
25,255.04
1,461.2
-7,748.53
-7,748.53
Book Value per Share
- -
22,520.74
9,744.92
7,030.01
4,541.92
3,745.81
17.55
1.11
39,602.04
80,413.92
82,194.17
69,688.88
13,922.65
-4,311.8
-7,748.53
-7,748.53
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
22
37
49
44
35
9
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
-147.66
-113.94
-54.1
-64.38
-41.97
-105.36
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
20
52
59
30
12
- -
Depreciation Expense
22
-20
-13
-4
-3
-1
- -
-21
-11
-33
-33
-48
-89
-40
-16
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-152.1
-88.17
-97.85
-200.97
-114.73
-174.17
- -
Profit Margin (%)
- -
6
5
3
- -
-1
1
1
-8
15
20
16
-4
-13
-20
-20
Working Capital
- -
- -
- -
- -
- -
- -
1
4
8
7
8
8
6
5
2
2
LT Debt
- -
26
11
8
5
4
- -
- -
100
136
144
117
33
-5
-21
-21
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-73.17
-43.21
-43.15
-19.21
-4.37
-13,793.49
-21.77
-27.7
-22.96
-36.24
-110.77
-184.99
- -
- -
Return on Common Equity (%)

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
11
11
10
LT Borrowings
1
1
1
LT Finance Leases
3
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
6
4
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
4
3
- -
Inventories
1
1
- -
Total Current Liabilities
20
20
21
Payables & Accruals
- -
- -
- -
ST Debt
11
11
10
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9,234.01%
18.22%
292.02%
Free Cash Flow
564.16%
-58.34%
-153.16%
Net Income, GAAP
2,174.02%
3.16%
-60.47%
Sales/Revenue/Turnover
- -
-0.22%
-73.96%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
44
2024
- -
- -
35
2025
- -
- -
9

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-70,525.64
2024
- -
- -
-23,947.64
2025
- -
- -
-9,329.19

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Patanjali Foods Limited (NSE:PATANJALI)
Tilray Brands, Inc. (NASDAQ:TLRY)
Archer-Daniels-Midland Company (NYSE:ADM)
Corteva, Inc. (NYSE:CTVA)
Canopy Growth Corporation (NASDAQ:CGC)
Balrampur Chini Mills Ltd (NSE:BALRAMCHIN)
Business
Tikun Olam-Cannbit Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company engaged in the research, cultivation, development, processing, and commercialization of pharmaceutical-grade medical cannabis products and cannabinoid-based therapies. The company operates a vertically integrated business structure encompassing agronomic breeding, proprietary genetics development, standardized clinical research, extraction and manufacturing, and patient-tailored commercial distribution. Its core product offerings include proprietary medical cannabis strains categorized by defined cannabinoid and terpene profiles; dried medical cannabis inflorescences; sublingual cannabis oil extracts and standardized drops; pre-measured cannabis formulations; vaporizer cartridges; and topical dermatological preparations. These offerings are marketed under well-established proprietary strain brand names, including Avidekel, Midnight, Alaska, Erez, Dorit, and Or, formulated for specific medical indications such as oncology-related symptom management, pediatric and adult epilepsy, autism spectrum disorders, Crohn's disease, fibromyalgia, neurodegenerative conditions, and chronic intractable pain. Tikun Olam-Cannbit also conducts extensive clinical trials and observational studies in collaboration with tertiary medical centers and academic research institutions. Founded in 2005 and headquartered in Israel, the company maintains agricultural and manufacturing operations in Israel and serves domestic healthcare markets as well as international jurisdictions through export programs and licensing arrangements, primarily across Europe, including Germany, the United Kingdom, and Poland. In recent developments, the company has undertaken operational streamlining and corporate realignment to enhance production efficiencies and capitalize on global export opportunities; entered into strategic distribution and supply partnerships with pharmaceutical distributors in Europe to supply EU-GMP compliant medical cannabis; expanded its portfolio of high-potency and terpene-enriched medical formulations; and advanced clinical partnerships focused on specialized cannabinoid therapeutics for elderly and pediatric patient populations.